Hamburg, Germany

Dermatologikum Hamburg

Atopic Dermatitis

Psoriasis

Dermatitis

Eczema

Actinic Keratosis

Conjunctivitis

Keratosis

Skin Diseases

Rhinitis

Upadacitinib

TAK-279

AMG 451

Enbrel

LY3375880

Dupilumab

Rocatinlimab

5-FU

CHS-0214

AbbVie

Lilly

Takeda

Amgen

Coherus BioSciences

HAL Allergie

Pierre Fabre

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis.

All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules.

Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Dermatologikum Hamburg | Hamburg, Germany

Site insights

Work at this site?

Active trials

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Trial sponsors